/
Other
Withdrawal
13
Pipeline Programs↗
15
Active Trials↗
17
Companies Involved↗
Withdrawal is an emerging landscape with 13 programs across 17 companies. The most active players are Bristol-Myers Squibb. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 1
No programs
Phase 23
Approved
No programs
Analysis
Trial Status
145
clinical trials
Completed98 · 68%
Terminated14 · 10%
Unknown status12 · 8%
Recruiting8 · 6%
Withdrawn6 · 4%
Not yet recruiting3 · 2%
Other4 · 3%
Clinical Trials
Trial Activity
145 trials
Pragmatic, Randomized, Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)
Active, not recruiting·AAdvancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program·Phase 3·NCT04214834·189 enrolled
Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients
Not yet recruiting·—·N/A·NCT07466875·60 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)